17.05.2022 Marinomed Biotech AG  ATMARINOMED6

DGAP-News: Marinomed to attend several upcoming investor conferences


DGAP-News: Marinomed Biotech AG / Key word(s): Conference
Marinomed to attend several upcoming investor conferences

17.05.2022 / 07:45
The issuer is solely responsible for the content of this announcement.

Marinomed to attend several upcoming investor conferences

Korneuburg, Austria, 17 May 2022 – Marinomed Biotech AG (VSE:MARI), an Austrian science-based biotech company with globally marketed therapeutics, today announced that Dr. Andreas Grassauer, CEO, Pascal Schmidt, CFO, and Stephanie Kniep, Head of Investor Relations, will be attending several upcoming investor conferences where they will be available for meetings:

German Spring Conference (link)
23 May 2022 – Frankfurt, Germany

Organized by Equity Forum, the annual German Spring Conference gives listed companies the opportunity to present to and connect with selected investors, analysts, financial journalists, and other capital market players.
Marinomed will attend on 23 May after presenting their Q1 financial results at 10:00 am CEST in a conference call. The presentation will be at 03:30 pm CEST.

8th Quirin Champions Conference 2022 (link)
01 June 2022 – online

At the 8th "Quirin Champions Conference", approximately 20 selected small and mid-caps present themselves to investors. Meetings can be booked via Quirin.

Oddo BHF Nextcap Forum (link)
02 June 2022 – online

The event brings together companies worth up to €1 bn and investors. Meetings can be booked via Oddo.

analytica Finance Days (link)
23 June 2022 – Munich, Germany

The Finance Days of Analytica are dedicated to start-up, growth, and capital market financing of life science companies.
Dr. Andreas Grassauer will attend and participate in a panel discussion on 23 June.

Other upcoming events:

Seaweed around the clock (link)
02 June 2022 – online

Spanning the globe, this 24-hour event is entirely dedicated to seaweed. Dr. Eva Prieschl-Grassauer, CSO, will participate in the Panel “Magic Seaweed – How can seaweed revolutionize the pharmaceutical sector?” at 12:00 pm CEST.

Marinomed Annual General Meeting (link)
15 June 2022 – Vienna, Austria

The invitation will be published later today. All information will then be available on Marinomed’s website www.marinomed.com.

About Marinomed Biotech AG
Marinomed Biotech AG is an Austrian, science-based biotech company with a growing development pipeline and globally marketed therapeutics. The Company develops innovative patent-protected products in the therapeutic areas immunology and virology based on the platform Marinosolv® and the virus-blocking activity of iota-carrageenan. The Marinosolv® technology improves the solubility and bioavailability of hardly soluble compounds and is used to develop new therapeutics for autoreactive immune disorders. The virology segment includes Carragelose®-based over-the-counter (OTC) products to prevent and treat respiratory viral infections that are partnered in more than 40 countries. Marinomed also develops drugs for other serious viral infectious diseases based on iota-carrageenan. The Company is headquartered in Korneuburg, Austria, and is listed on the prime market of the Vienna Stock Exchange (VSE:MARI). For further information, please visit: https://www.marinomed.com.

For further inquiries contact:

Marinomed Biotech AG                        
PR: Lucia Mayr-Harting

T +43 2262 90300 158
Email: [email protected]
IR: Stephanie Kniep
T +43 2262 90300 226
Email: [email protected]
International Media Contact
MC Services AG

Dr. Brigitte Keller, Dr. Regina Lutz
T +49 89 210228 0
UK: Shaun Brown
M: +44 7867 515 918
Email: [email protected]

This press release contains forward-looking statements, which are based on current views, expectations and projections of the management of Marinomed Biotech AG about future events. These forward-looking statements are subject to risks, uncertainties and assumptions that could cause actual results, performance or events to differ materially from those described in, or expressed or implied by, such statements. The current views, expectations and projections of the management of Marinomed Biotech AG may be identified by the context of such statements or words such as “anticipate,” “believe”, “estimate”, “expect”, “intend”, “plan”, “project” and “target”. Forward-looking statements are only valid as of the date they are made and Marinomed Biotech AG does not assume any obligation to update, review or revise any forward-looking statements contained in this press release whether as a result of new information, future developments or otherwise. Marinomed, Marinosolv® and Carragelose® are registered trademarks of Marinomed Biotech AG. These trademarks may be owned or licensed in select locations only.

17.05.2022 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de

Language: English
Company: Marinomed Biotech AG
Hovengasse 25
2100 Korneuburg
Phone: +43 2262 90300
Fax: +43 2262 90300-500
E-mail: [email protected]
Internet: www.marinomed.com
Listed: Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt, Munich, Stuttgart, Tradegate Exchange; Vienna Stock Exchange (Official Market)
EQS News ID: 1353655

End of News DGAP News Service

1353655  17.05.2022 


Die wichtigsten Finanzdaten auf einen Blick
  2016 2017 2018 2019 2020 2021 2022
Umsatzerlöse1 2,61 4,81 4,67 6,14 8,12 11,63 11,28
EBITDA1,2 -1,34 -1,44 -4,90 -5,88 -5,39 -3,54 -4,24
EBITDA-Marge3 -51,34 -29,94 -104,93 -95,77 -66,38 -30,44 -37,59
EBIT1,4 -1,53 -1,64 -5,14 -6,21 -5,82 -4,14 -4,91
EBIT-Marge5 -58,62 -34,10 -110,06 -101,14 -71,67 -35,60 -43,53
Jahresüberschuss1 -1,97 -2,38 -12,10 -7,22 -6,01 -5,89 -6,40
Netto-Marge6 -75,48 -49,48 -259,10 -117,59 -74,01 -50,65 -56,74
Cashflow1,7 -2,53 -2,18 -4,32 -7,64 -6,89 -4,87 -5,20
Ergebnis je Aktie8 -1,97 -2,38 -12,10 -5,10 -4,10 -4,00 -4,30
Dividende8 0,00 0,00 0,00 0,00 0,00 0,00 0,00
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2022 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: BDO

Marinomed Biotech
WKN Kurs in € Einschätzung Börsenwert in Mio. €
A2N9MM 43,700 Halten 66,39
KGV 2024e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
0,00 0,00 0,00 -9,44
-15,97 - 5,89 -19,05
Dividende '22 in € Dividende '23e in € Div.-Rendite '22e
in %
0,00 0,00 0,00 21.06.2023
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
23.05.2023 17.08.2023 21.11.2023 19.04.2023
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
19,21% -12,03% -22,24% -40,79%
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu Marinomed Biotech AG  ISIN: ATMARINOMED6 können Sie bei EQS abrufen

Biotechnologie , A2N9MM , MBG , FWB:MBG